BioAge ^Company

BioAge's mission is to develop a pipeline of therapeutic assets that increase healthspan and lifespan.They are building deep molecular profiles of these samples, incorporating proteomics, metabolomics, and transcriptomics to identify the best drug targets for healthy aging. The Hypoxia-inducible factor (HIF) pathway is linked to lifespan and healthspan in BioAge’s proprietary human aging data. Pathway activation levels are significantly associated with longevity and multiple functional measures. BGE-117 is a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor that can potentially treat multiple diseases of aging through the activation of HIF-1 target genes that are involved in numerous biological processes including tissue regeneration, erythropoiesis, glycolysis, glucose uptake, vascular remodeling and angiogenesis.